Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Oxford BioMedica plc    OXB   GB0006648157

OXFORD BIOMEDICA PLC (OXB)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
10.12(c) 9.56(c) 9.75(c) 10.04(c) 10.4(c) Last
15 947 450 14 151 176 15 933 916 16 930 917 8 629 497 Volume
+6.53% -5.53% +1.99% +2.97% +3.59% Change
More quotes
Financials ( GBP)
Sales 2017 36,6 M
EBIT 2017 -4,93 M
Net income 2017 -6,33 M
Debt 2017 16,6 M
Yield 2017 -
Sales 2018 44,2 M
EBIT 2018 -0,25 M
Net income 2018 -0,63 M
Debt 2018 13,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 8,98x
EV / Sales2018 7,37x
Capitalization 312 M
More Financials
Company
Oxford Biomedica Ltd. operates as a biopharmaceutical company, which focus on biotechnology research and development, and the related manufacturing.It operates through the Partnering and R&D segments.The Partnering segment provides lentiviral vector bioprocessing and process development services to... 
More about the company
Surperformance© ratings of Oxford BioMedica plc
Trading Rating : Investor Rating :
More Ratings
Latest news on OXFORD BIOMEDICA PLC
01/17 OXFORD BIOMEDICA : notes the US FDA Priority Review for Kymriah™ for adult..
2017 OXFORD BIOMEDICA : notes the primary analysis results from the pivotal JULIET tr..
2017 OXFORD BIOMEDICA : notes the CTL019 MAA submission to the EMA for children, youn..
2017 OXFORD BIOMEDICA : Boost For Oxford Biomedica As Novartis Files For Further Bloo..
2017 OXFORD BIOMEDICA : notes the sBLA submission to FDA for Kymriah™ in adult ..
2017 Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult pa..
2017 OXFORD BIOMEDICA : 5.1% Potential Decrease Indicated by N+1 Singer
2017 OXFORD BIOMEDICA : CTL019 receives FDA approval for paediatric, young adult r/r ..
2017 OXFORD BIOMEDICA : announces a £2 million two-year collaboration co-funded by In..
2017 OXFORD BIOMEDICA : Announces MHRA Licence For Commercial Supply
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/17Oxford BioMedica : notes the US FDA Priority Review for Kymriahâ„¢ for adults.. 
01/08Oxford BioMedica's buy rating reiterated at Peel Hunt. GBX 13 PT.  
01/05$OXBDF - Oxford Biomedica #OXBDF Rating Lowered to Sell at ValuEngine  
2017Oxford BioMedica : notes the primary analysis results from the pivotal JULIET.. 
2017$OXB - Peel Hunt Reaffirms "Buy" Rating for Oxford BioMedica plc #OXB  
More tweets
Qtime:551
News from SeekingAlpha
2017 Oxford Biomedica PLC reports 1H results
2017 The CTL019 Adcom Mists Begin To Clear
2017 Oxford BioMedica (OXBDF) Presents At Jefferies 2017 Global Healthcare Confere..
2017 SNIPPET ROUNDUP : Novartis' Allogeneic CAR-T Drive And Astra's IL-4 Interest
2017 Oxford BioMedica's (OXBDF) CEO John Dawson on Q4 2016 Results - Earnings Call..
Chart OXFORD BIOMEDICA PLC
Duration : Period :
Oxford BioMedica plc Technical Analysis Chart | OXB | GB0006648157 | 4-Traders
Technical analysis trends OXFORD BIOMEDICA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 0,14  GBP
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
John Dawson Chief Executive Officer & Executive Director
Lorenzo M. Tallarigo Non-Executive Chairman
Stuart Paynter Chief Financial Officer & Director
Kyriacos Mitrophanous Chief Scientific Officer
James Miskin Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD BIOMEDICA PLC10.17%434
GILEAD SCIENCES12.02%104 801
REGENERON PHARMACEUTICALS-1.53%39 775
VERTEX PHARMACEUTICALS3.90%39 380
GENMAB12.29%11 532
EXELIXIS, INC.-2.47%8 772